Celldex Therapeutics Inc. said it would discontinue the development of two other investigational drugs for cancer indications.
The drugs are CDX-014, in early phase 1 development for renal and ovarian cancers, and CDX-1401, in phase 2 development for multiple solid tumors.
The Hampton, N.J.-based drug developer had earlier terminated its investigational drug glembatumumab vedotin after it failed a phase 2 study in breast cancer.
Celldex had said it would focus on five other drug candidates, including CDX-014, and later decided to cut 41 jobs to save resources.
In 2018, the company expects to focus primarily on developing two potential cancer drugs — CDX-1140 and CDX-3379 — Celldex President and CEO Anthony Marucci said in a statement.